Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma

Universiti Kebangsaan Malaysia Medical Centre40 enrolled

Overview

Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is constantly associated with progression of visual field loss. Medical therapy is the first line in IOP reduction for Primary Open Angle Glaucoma (POAG). It is a known fact that glaucoma patients often require addition of a second antiglaucoma medications when disease progresses or tachyphylaxis occurs. It was reported that more than 50% of patients require 2 or more medications to achieve optimum IOP control. Nevertheless, compliance and adherence are often impaired with multiple-drug therapy. Combining two ocular hypotensive agents in one bottle may help patients adhere to therapeutic regimen by reducing the number of medications used and the total number of doses administered.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Primary Open Angle Glaucoma

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age 18 and above 2. Able to provide informed consent 3. Diagnosed as having unilateral or bilateral, mild to moderate POAG 4. The POAG treated with only two antiglaucoma Exclusion Criteria: 1. Advanced POAG 2. Patient with contraindication for topical use of a-blocker and prostaglandin analogue 3. Patient with contraindication for systemic use of a-blocker 4. Patient on systemic use of a-blocker such as metoprolol, propranolol, atenolol 5. History of orbital or ocular trauma. 6. History of cataract surgery less than 6 months. 7. History of previous ocular surgery; e.g. vitreoretinal surgery, corneal transplantation or glaucoma surgery 8. Any active eye infections or corneal ulceration. 9. Patient with ocular surface disease 10. Other ocular disease that might interfere with IOP measurements or result 11. Precious eye i.e patient with only one good eye 12. Contact lens is not allowed within 1 week before the start of study and during the study

Outcomes

Primary Outcomes

Efficacy: Intraocular pressure reduction

IOP reduction with LTFC given once and twice daily in POAG patients

Time frame: 4 weeks

Secondary Outcomes

Safety: Side effects

Side effects of LTFC given twice daily in POAG patients